Index Ventures spinout Medicxi Ventures has launched with a $230m first fund backed by GlaxoSmithKline and Johnson & Johnson.

European venture capital firm Medicxi Ventures closed its first fund, Medicxi Ventures 1 (MV1), at €210m ($230m) today with contributions from healthcare firms GlaxoSmithKline (GSK) and Johnson & Johnson.

Based in London, Geneva and Jersey, Medicxi Ventures acts as a spin out of VC firm Index Ventures, taking forward its legacy life sciences portfolio companies, funds and team.

GSK and Johnson & Johnson, which invested in the fund through its Johnson & Johnson Innovation – JJDC unit, had previously been…